Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BJT-778 in chronic hepatitis B infection
ACTRN12623000111673Phase 2Active, not recruiting
- Sponsor
- Bluejay Therapeutics
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of brelovitug and nivolumab in Chronic Hepatitis B (CHB), sponsored by Bluejay Therapeutics. Primary endpoint: Safety and tolerability of BJT-778. Started Feb 2024; status: active, not recruiting.
02
Drugs
brelovitugnivolumab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12623000111673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000111673.